New ATC code Substance name Deadline for objections Implementation in the

ATC/DDD index (Year) Comment

A02BC51 omeprazole, combinations Final 2024
A02BD17 vonoprazan and amoxicillin Final 2024
A02BX16 irsogladine Final 2024
A05AA05 ursodoxicoltaurine Final 2024
A07FA03 escherichia coli Final 2024
A10AE07 insulin icodec Final 2024
A10BD28 metformin and teneligliptin Final 2024
A10BD29 sitagliptin and dapagliflozin Final 2024
A16AB26 eladocagene exuparvovec Final 2024
A16AB27 pabinafusp alfa Final 2024
A16AX23 leriglitazone Final 2024
B01AF51 rivaroxaban and acetylsalicylic acid Final 2024
B02BD15 valoctocogene roxaparvovec Final 2024
B02BX10 concizumab Final 2024
B06AX05 exagamglogene autotemcel Final 2024
C01CA28 centhaquine Final 2024
C01CX10 omecamtiv mecarbil Final 2024
C05AX06 phenylephrine Final 2024
C05XX01 beperminogene perplasmid Final 2024
C09BX06 perindopril, bisoprolol, amlodipine and indapamide Final 2024
C10BX20 rosuvastatin and telmisartan Final 2024
D05AX06 roflumilast Final 2024
D05AX07 tapinarof Final 2024
G04BD15 vibegron Final 2024
G04BX17 sodium salicylate and methenamine Final 2024
J01DC52 cefuroxime and beta-lactamase inhibitor Final 2024
J01DE51 cefepime and beta-lactamase inhibitor Final 2024
J07BN05 covid-19, virus-like particles Final 2024
J07BX05 respiratory syncytial virus vaccines Final 2024
L01BC58 decitabine, combinations Final 2024
L01EJ04 momelotinib Final 2024
L01EK04 fruquintinib Final 2024
L01EL04 orelabrutinib Final 2024
L01EL05 pirtobrutinib Final 2024
L01FF11 sugemalimab Final 2024
L01FF12 serplulimab Final 2024
L01FX24 teclistamab Final 2024
L01FX25 mosunetuzumab Final 2024
L01XK52 niraparib and abiraterone Final 2024
L01XL08 lisocabtagene maraleucel Final 2024
L01XL09 tabelecleucel Final 2024
L02BA04 elacestrant Final 2024
L02BX53 abiraterone and prednisolone Final 2024
L03AB17 sampeginterferon beta-1a Final 2024
L03AX22 leniolisib Final 2024
L04AC24 mirikizumab Final 2024
L04AC25 levilimab Final 2024
L04AF08 ritlecitinib Final 2024
L04AG15 divozilimab Final 2024
L04AJ06 zilucoplan Final 2024
M01AE57 naproxen and diphenhydramine Final 2024
M04AC51 colchicine and probenecid Final 2024
M09AX14 givinostat Final 2024
N02AD51 pentazocine and naloxone Final 2024
N02AJ22 hydrocodone and paracetamol Final 2024
N02AJ23 hydrocodone and ibuprofen Final 2024
N02BA67 magnesium salicylate, combinations excl. psycholeptics Final 2024
N02CC51 sumatriptan and naproxen Final 2024
N05CJ03 daridorexant Final 2024
N06DX04 lecanemab Final 2024
N07XX19 sodium phenylbutyrate and ursodoxicoltaurine Final 2024
N07XX21 eplontersen Final 2024
P02BA03 arpraziquantel Final 2024
S01AA32 bacitracin Final 2024
S01AX24 polihexanide Final 2024
S01BA16 difluprednate Final 2024
S01CA12 loteprednol and antiinfectives Final 2024
S01XA31 pegcetacoplan Final 2024
V03AB54 pralidoxime and atropine Final 2024
A01AB53 chlorhexidine and cetylpyridinium 9/1/2023 2024
A05AX06 elafibranor 9/1/2023 2024
A10BK08 bexagliflozin 9/1/2023 2024
A10XX01 teplizumab 9/1/2023 2024
B01AC28 limaprost 9/1/2023 2024
B01AD13 apadamtase alfa and cinaxadamtase alfa 9/1/2023 2024
B02BD16 etranacogene dezaparvovec 9/1/2023 2024
B05XA19 calcium gluconate 9/1/2023 2024
B05XA20 sodium selenite 9/1/2023 2024
C02KN01 aprocitentan 9/1/2023 2024
C04AX33 clazosentan 9/1/2023 2024
C09BX07 zofenopril and nebivolol 9/1/2023 2024
C10AB12 pemafibrate 9/1/2023 2024
C10BX21 rosuvastatin and perindopril 9/1/2023 2024
D03AX16 beremagene geperpavec 9/1/2023 2024
D11AH10 lebrikizumab 9/1/2023 2024
D11AH11 delgocitinib 9/1/2023 2024
D11AH12 nemolizumab 9/1/2023 2024
H02AB18 vamorolone 9/1/2023 2024
H05AA05 palopegteriparatide 9/1/2023 2024
H05BX06 evocalcet 9/1/2023 2024
J01DD58 cefixime and beta-lactamase inhibitor 9/1/2023 2024
J05AE11 ensitrelvir 9/1/2023 2024
J05AP13 ravidasvir 9/1/2023 2024
J05AR28 stavudine and lamivudine 9/1/2023 2024
J07BX06 enterovirus 71 vaccines 9/1/2023 2024
L01EX26 sitravatinib 9/1/2023 2024
L01EX27 capivasertib 9/1/2023 2024
L01FF13 toripalimab 9/1/2023 2024
L01FX26 mirvetuximab soravtansine 9/1/2023 2024
L01FX27 epcoritamab 9/1/2023 2024
L01FX28 glofitamab 9/1/2023 2024
L01FX29 talquetamab 9/1/2023 2024
L01FY03 prolgolimab and nurulimab 9/1/2023 2024
L01XL10 nadofaragene firadenovec 9/1/2023 2024
L01XL11 lifileucel 9/1/2023 2024
L01XX78 navitoclax 9/1/2023 2024
L01XX79 eflornithine 9/1/2023 2024
L01XX80 imetelstat 9/1/2023 2024
L03AA19 eflapegrastim 9/1/2023 2024
L04AE05 etrasimod 9/1/2023 2024
L04AG16 rozanolixizumab 9/1/2023 2024
L04AJ07 crovalimab 9/1/2023 2024
L04AJ08 iptacopan 9/1/2023 2024
L04AJ09 danicopan 9/1/2023 2024
M09AX15 delandistrogene moxeparvovec 9/1/2023 2024
N06AX62 bupropion and dextromethorphan 9/1/2023 2024
N06DX05 donanemab 9/1/2023 2024
N07XX22 tofersen 9/1/2023 2024
N07XX23 troriluzole 9/1/2023 2024
R03AK15 salbutamol and budesonide 9/1/2023 2024
S01HA08 chloroprocaine 9/1/2023 2024
V04CX11 lithium chloride 9/1/2023 2024
V09IA10 technetium (99mTc) trofolastat chloride 9/1/2023 2024
ATC code New ATC level name Deadline for objections Implementation in the
ATC/DDD index (Year)
C05X OTHER VASOPROTECTIVES Final 2024
C05XX Other vasoprotectives Final 2024
L04AE Sphingosine 1-phosphate (S1P) receptor modulators Final 2024
L04AF Janus-associated kinase (JAK) inhibitors Final 2024
L04AG Monoclonal antibodies Final 2024
L04AH Mammalian target of rapamycin (mTOR) kinase inhibitors Final 2024
L04AJ Complement inhibitors Final 2024
L04AK Dihydroorotate dehydrogenase (DHODH) inhibitors Final 2024
N05CJ Orexin receptor antagonists Final 2024
A10XX Other drugs used in diabetes 9/1/2023 2024
C02KN Other antihypertensives 9/1/2023 2024
L01FY Combinations of monoclonal antibodies and antibody drug conjugates 9/1/2023 2024
Previous ATC code ATC level name New ATC code Deadline for objection to Implementation in the Note
temporary ATC code ATC/DDD index (Year)

L04AA02 muromonab-CD3 L04AG01 Final 2024

L04AA10 sirolimus L04AH01 Final 2024
L04AA13 leflunomide L04AK01 Final 2024
L04AA18 everolimus L04AH02 Final 2024
L04AA21 efalizumab L04AG02 Final 2024
L04AA23 natalizumab L04AG03 Final 2024
L04AA25 eculizumab L04AJ01 Final 2024
L04AA26 belimumab L04AG04 Final 2024
L04AA27 fingolimod L04AE01 Final 2024
L04AA29 tofacitinib L04AF01 Final 2024
L04AA31 teriflunomide L04AK02 Final 2024
L04AA33 vedolizumab L04AG05 Final 2024
L04AA34 alemtuzumab L04AG06 Final 2024
L04AA35 begelomab L04AG07 Final 2024
L04AA36 ocrelizumab L04AG08 Final 2024
L04AA37 baricitinib L04AF02 Final 2024
L04AA38 ozanimod L04AE02 Final 2024
L04AA39 emapalumab L04AG09 Final 2024
L04AA42 siponimod L04AE03 Final 2024
L04AA43 ravulizumab L04AJ02 Final 2024
L04AA44 upadacitinib L04AF03 Final 2024
L04AA45 filgotinib L04AF04 Final 2024
L04AA46 itacitinib L04AF05 Final 2024
L04AA47 inebilizumab L04AG10 Final 2024
L04AA49 peficitinib L04AF06 Final 2024
L04AA50 ponesimod L04AE04 Final 2024
L04AA51 anifrolumab L04AG11 Final 2024
L04AA52 ofatumumab L04AG12 Final 2024
L04AA53 teprotumumab L04AG13 Final 2024
L04AA54 pegcetacoplan L04AJ03 Final 2024
L04AA55 sutimlimab L04AJ04 Final 2024
L04AA56 deucravacitinib L04AF07 Final 2024
L04AA57 ublituximab L04AG14 Final 2024
L04AA59 avacopan L04AJ05 Final 2024
N05CM19 suvorexant N05CJ01 Final 2024
N05CM21 lemborexant N05CJ02 Final 2024
L01XY02 pertuzumab and trastuzumab L01FY01 9/1/2023 2024
L01XY03 nivolumab and relatlimab L01FY02 9/1/2023 2024
 Deadline for objection to
temporary ATC level
ATC code Previous ATC level name New ATC level name name
J07BX01 smallpox vaccines smallpox and monkeypox vaccines Final
D03AX14 Centella asiatica herba Centella asiatica herba, incl. combinations 9/1/2023
 Implementation in
the ATC/DDD index
(Year)
2024
2024
 Deadline for objection to Implementation in the
ATC code ATC level name New DDD Unit Adm.route temporary DDD ATC/DDD index (Year) Note
A10BH08 teneligliptin 20 mg O Final 2024
C03DA05 finerenone 20 mg O Final 2024
H02CA02 osilodrostat 10 mg O Final 2024
J01AA13 eravacycline 0.14 g P Final 2024
J01DC52 cefuroxime and beta-lactamase inhibitor 0.5 g O Final 2024 refers to cefuroxime
J01DI04 cefiderocol 6g P Final 2024
J05AH04 laninamivir 0.16 g Inhal.solution Final 2024
J05AX28 bulevirtide 2 mg P Final 2024
L01EX21 tepotinib 0.45 g O Final 2024
L04AA51 anifrolumab 10.7 mg P Final 2024 New ATC 5th level to be included in the
L04AC19 satralizumab 4.3 mg P Final 2024
N02CC08 lasmiditan 0.1 g O Final 2024
A07AA13 rifamycin 0.8 g O 9/1/2023 2024 as sodium salt
B06AX04 mitapivat 0.1 g O 9/1/2023 2024
G04BD15 vibegron 75 mg O 9/1/2023 2024
H05BX06 evocalcet 2.5 mg O 9/1/2023 2024
J02AA01 amphotericin B 210 mg P 9/1/2023 2024 lipid formulations
J02AC06 oteseconazole 21 mg O 9/1/2023 2024
J04AK08 pretomanid 0.2 g O 9/1/2023 2024
J05AE11 ensitrelvir 0.175 g O 9/1/2023 2024
J05AP13 ravidasvir 0.2 g O 9/1/2023 2024
J05AX10 maribavir 0.8 g O 9/1/2023 2024
J05AX24 tecovirimat 1.2 g O 9/1/2023 2024
J05AX31 lenacapavir 0.19 g O 9/1/2023 2024
J05AX31 lenacapavir 5.1 mg P 9/1/2023 2024
L01EA06 asciminib 80 mg O 9/1/2023 2024
L01EL04 orelabrutinib 0.15 g O 9/1/2023 2024
L04AC22 spesolimab 0.9 g P 9/1/2023 2024 course dose
L04AD03 voclosporin 47.4 mg O 9/1/2023 2024
L04AA03 antilymphocyte immunoglobulin (horse) 1.05 g P 9/1/2023 2024
L04AA54 pegcetacoplan 0.3 g P 9/1/2023 2024
N02CD05 eptinezumab 1.1 mg P 9/1/2023 2024
R05DB29 gefapixant 90 mg O 9/1/2023 2024
V03AX04 difelikefalin 15 mcg P 9/1/2023 2024
efers to cefuroxime

New ATC 5th level to be included in the new ATC 4th level L04AG Monoclonal antibodies in the Index 2024

s sodium salt

pid formulations
ATC code ATC level name Previous Unit Adm.r New DDD Unit Adm.r Note Deadline for Implementation Note
DDD oute oute objection to in the ATC/DDD
temporary DDD index (Year)
A07EA06 budesonide 2 mg SL 1.5 mg SL 9/1/2023 2024